Serum tumor markers and PET/CT imaging for tumor recurrence detection

Loading...
Thumbnail Image

Authors

Kruse, Vibeke
Cocquyt, Veronique
Borms, Marleen
Maes, Alex
Van de Wiele, Christophe

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

Abstract

When confronted with a suspicious rise in CA 15.3 in asymptomatic breast cancer patients following primary treatment and negative or equivocal conventional imaging findings, FDG PET/CT allows assessment of the site and extent of the recurring disease with an accuracy of 83 %. Both FDG PET and FDG PET/CT are superior when compared to CT alone for the purpose of recurrence detection in patients suffering from ovarian carcinoma who have completed primary therapy but demonstrate a rising serum CA-125 level. As the global accuracy of CT alone for detection of recurrence of ovarian cancer approximates 80 %, CT scan should be performed upfront to identify the site of recurrence. When confronted with negative or equivocal CT findings, FDG PET alone or FDG PET/CT should be added. In patients with rising serum CEA levels that have undergone primary treatment for a colorectal carcinoma, both FDG PET and FDG PET/ CT allow detection of tumor recurrence with an accuracy of 95 %, well above that of CT and MRI. Available studies further suggest that FDG/PET findings will affect treatment management in 28–50 % of these patients. The detection rate of both 11C-choline and 18F-choline PET and PET/CT for local, regional, and distant recurrence in prostate carcinoma patients with a biochemical recurrence increases with rising PSA value at the time of imaging and reaches about 75 % in patients with PSA[3 ng/mL. Furthermore, PET and PET/CT with [11C]- and [18F]- choline derivates may be helpful in the clinical setting for optimization of individualized treatment.

Description

Keywords

Serum tumor markers, FDG PET/CT, Tumor recurrence, PET/CT, Breast cancer, Ovarian cancer, Colorectal cancer, Prostate carcinoma, Positron emission tomography (PET), Computerized tomography' (CT), Fluorine-18-Fluorodeoxyglucose (FDG)

Sustainable Development Goals

Citation

Kruse, V, Cocquyt, V, Borms, M, Maes, A & Van de Wiele, C 2013, 'Serum tumor markers and PET/CT imaging for tumor recurrence detection', vol. 27, no. 2, pp. 97-104.